ascending dose

ascending dose

The administration of increasing doses of a drug until a desired effect is achieved.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
In the first phase, study volunteers receive a single dose of TERN-201 or placebo in ascending dose cohorts.
In the second phase of the study, healthy participants receive repeat doses of TERN-201 or placebo, also in ascending dose cohorts.
The planned study will be performed in two phases, a Single Ascending Dose (SAD) phase with five cohorts and a Multi Ascending Dose (MAD) phase with three cohorts.
The two E2609 Phase I studies presented at the AAIC 2012 comprised a single oral ascending dose study (Study A001-001) which showed Abeta levels reduction in plasma, and a 14-day multiple oral ascending dose study (Study A001-002) which showed dose-dependent increase of E2609 PK level and statistically significant reduction of Abeta levels in cerebrospinal fluid (CSF).
Data from this single and multiple ascending dose study demonstrated that CH-4051 is safe and well tolerated up to a maximally tolerated dose of 7.5mg.
The Phase I trial of V24343, a CB1 antagonist, will be a double-blind, randomized, placebo-controlled study in overweight and mildly obese volunteers and will be conducted in two parts: a single ascending dose followed by a multiple ascending dose.
The TAFA93 Phase Ia single center, randomized, placebo-controlled, Single Ascending Dose (SAD) trial began in July 2004.
The study comprised six ascending dose groups each given CDP-791 intravenously once every three weeks.
Hepion Pharmaceuticals announced that it has dosed the first patient in a 28-day multiple ascending dose clinical trial of CRV431.
(Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, announced today that it has completed dosing in a single ascending dose (SAD) Phase 1 study of APVO210, a novel investigational bispecific antibody candidate being developed for the treatment of autoimmune diseases.
It has successfully completed Phase 1 single ascending dose/multiple ascending dose clinical trials in healthy volunteers demonstrating a superior pharmacokinetic profile with a half-life of 30 hours, enabling an easy-to-use, once-weekly dosing regimen.